FDA approves 2 hep C drugs from AbbVie, BMS
This article was originally published in Scrip
Executive Summary
The FDA was on a roll on 24 July, granting five approvals, including to two hepatitis C virus (HCV) medicines: AbbVie's Technivie (ombitasvir/paritaprevir/ritonavir) and Bristol-Myers Squibb's Daklinza (daclatasvir).